Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as LY3461767 - SC
LY3461767 · 1 trial · 1 indication
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY3461767 | EXPERIMENTAL | LY3461767 administered subcutaneously (SC). |
| Placebo | PLACEBO_COMPARATOR | Placebo administered subcutaneously (SC). |
| Name | Type | Description |
|---|---|---|
| LY3461767 | DRUG | Administered SC. |
| Placebo | DRUG | Administered SC. |
Inclusion Criteria: * Are males and in agreement to follow contraceptive requirements, or women of non-child-bearing potential * Have a body mass index (BMI) of \</= 45.0 kilograms per square meter (kg/m²) * Have chronic stable heart failure (New York Heart Association (NYHA) classification II and ...
LY3461767 is being studied for chronic heart failure with reduced ejection fraction, a condition in which the heart muscle does not pump blood as effectively as it should. It is an investigational small molecule developed by Eli Lilly and Company and has not been approved for any use.
LY3461767 is developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. The company is the sponsor of the clinical program evaluating the drug in chronic heart failure with reduced ejection fraction.
LY3461767 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The drug remains investigational and has not been approved by the FDA or any other regulatory agency.
LY3461767 has been evaluated in one completed Phase 1 trial, NCT04840914, titled A Study of LY3461767 in Participants With Chronic Heart Failure With Reduced Ejection Fraction. The trial enrolled 44 participants across the United States and Japan and was randomized, double blind, and placebo controlled.
Yes, LY3461767 - SC is an alternative name used for LY3461767, the same investigational small molecule developed by Eli Lilly and Company for chronic heart failure with reduced ejection fraction. Searches for either name refer to the same drug asset.